800 Health Care

Junshi Biosciences' Toripalimab Combined with RemeGen's RC48 Approved for New Indication

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Asymchem Tianjin to convene 2nd H-share AGM on June 10 to vote on A-share buyback authorization

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

399933

中证医疗

000933

159506

512170

159303

512010

159929

513060

560260

The General Office of the State Council has issued an opinion to improve the price formation mechanism for centralized volume-based drug procurement, promote standardization and normalization of drug procurement, and expand channels for docking between pharmaceutical enterprises and medical institutions. The opinion emphasizes demand orientation and quality priority, aiming to form reasonable prices through fair competition while optimizing procurement rules to ensure drug quality and stable supply. Additionally, it strengthens policy coordination between medical insurance payment standards and procurement prices, ensuring that payment standards for drugs within the medical insurance catalog are based on the winning bid prices

Wallstreetcn

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP CSI Medical Service ETF

Dacheng Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

China Universal 800 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

GF Fund CSI Medical Service ETF

State Council Office: Improve the Price Formation Mechanism for Centralized Volume-Based Drug Procurement and Enhance Management of Listed Drug Prices

588860

560600

562600

In Thursday's intraday session, Onconetix (NASDAQ:ONCO) saw a significant gain of 73.5%, reaching $1.96. Other notable gainers included Zentalis Pharmaceuticals (NASDAQ:ZNTL) up 43.1% to $3.95, and Forte Biosciences (NASDAQ:FBRX) up 29.04% to $33.9. Conversely, Annovis Bio (NYSE:ANVS) experienced a decline of 27.4% to $1.67, while Wellgistics Health (NASDAQ:WGRX) fell 17.78% to $0.1. Overall, several health care stocks showed considerable movement in both directions during the session.

benzinga_article

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI All Share Health Care Devices ETF

12 Health Care Stocks Moving In Thursday's Intraday Session

601677

PICK

U.S. President Donald Trump announced 100% tariffs on certain branded pharmaceutical imports, with exemptions reducing rates to 0% for many companies. Tariffs on branded drugs will be capped at 15% under trade agreements with the EU, Japan, South Korea, and Switzerland. A separate deal with Britain guarantees zero tariffs on British-made pharmaceuticals for three years. Additionally, Trump halved the duty rate to 25% on many derivative metal products and maintained a 50% duty on commodity imports of steel, aluminum, and copper.

Trading Economics

Mtalco

ISHRS MSCI Glb Slct Met & Mining

Freeport Mcmoran

Teck Resources B

NANSHAN ALUMINIUM

Invesco DB TR Base Metals ETF

Sprott Junior Copper Miners ETF

Sprott Copper Miners ETF

Southern Copper

CHALCO

Huafon Aluminium

JCCL

Century Aluminum

Global X Copper Miners

United States Copper Index

Alcoa

USCF Sustainable Battery Metals Strategy Fund ETF

Trump Unveils Up to 100% Tariff on Some Pharmaceuticals, Adjusts Metals

00HSI

00388

512290

516930

516820

159102

Hong Kong has seen over 10 loss-making biotech companies file for stock exchange listings this year, driven by a boom in AI drug research. The healthcare and biotech capital market reached US$15.6 billion last year, the second highest globally. Notable firms include Hangzhou Diagens Biotechnology and Exegenesis Bio, both utilizing AI in drug discovery. HKEX is reforming listing rules to support these companies, proposing to lower valuation thresholds and ease listing barriers. Investor interest in scalable, tech-enabled healthcare solutions is growing, with many pre-profit drug makers preparing for IPOs.

SCMP

Hang Seng Index

HKEX

Mustang Bio

CS精准医

Hong Kong Exchanges and Clearing (HKEX)

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

VanEck Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

159883

520690

516610

Annovis Bio reported a net loss of $28.9 million for the year, an increase from $24.6 million in 2024, primarily due to higher clinical spending. The company has $19.5 million in cash, which is insufficient to fund operations beyond 12 months, providing a runway into Q3 2026. Key highlights include a pivotal Phase 3 Alzheimer’s trial and a Parkinson’s disease extension study. R&D expenses rose to $25.2 million, while general and administrative costs decreased. Additional fundraising is critical for ongoing trials and operations.

TradingView

GF CSI All Share Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Dacheng CSI All Share Health Care Equipment and Services ETF

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026

159892

Avanos Medical, Inc. (NYSE: AVNS) based in Alpharetta, Georgia, is set to host a conference call on Feb. 24, 2026, at 9 a.m. Eastern Time to discuss the financial results and key business highlights for the fourth quarter and full year of 2025. This webcast will be available to the public. The company will also release a detailed news statement providing further information.

Unusual Whales

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Avanos Medical, Inc. (NYSE: AVNS) to discuss Q4 and full year 2025 financial results on Feb. 24 at 9 a.m. ET through webcast.

Distillate Capital Partners announced portfolio changes for Q4 2025, including purchases and sales across various strategies. The U.S. Fundamental Stability & Value Composite acquired Bristol-Myers Squibb, Vistra, and TE Connectivity, while selling Elevance Health, HCA Healthcare, and Lowe's. The U.S. Small/Mid Cap Quality & Value Composite bought CF Industries, Molson Coors, and Toll Brothers, exiting Range Resources, Gap, and TopBuild. Internationally, the strategy added Agnico Eagle Mines, HD HYUNDAI, and Rio Tinto, divesting from SK Hynix, LVMH, and Aluminum Corporation of China. Changes also included adjustments in stakes for several companies.

800 Health Care(000933.SH)